Q-omics provides the consensus-scored G0S2 profile across patient tissues and cancer cell-line models. G0S2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, G0S2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, G0S2 RNA expression shows 18,862 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where G0S2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for G0S2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes G0S2 survival associations across molecular data types. G0S2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible G0S2 RNA expression–survival associations across cancer types. High G0S2 expression shows unfavorable associations in UVM, KIRP, LGG, STAD and KIRC, but favorable associations in ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for G0S2 RNA expression.
This table summarizes G0S2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for G0S2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. G0S2 shows lower tumor expression in KIRP, BRCA, BLCA and KIRC and higher tumor expression in THCA and COAD. The THCA box plot shows higher G0S2 RNA expression in tumor versus normal tissue (log2 FC = +2.394, t-test p < 0.001).
This table shows molecular features associated with G0S2 in patient tissues and cancer cell lines. In patient samples, G0S2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, G0S2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
